Condition
Cardiogenic Shock Post Myocardial Infarction clinical trials and research
As of November 12, 2026, Find a Trial lists 6 Cardiogenic Shock Post Myocardial Infarction clinical trials that are recruiting, at sites in 6 countries (most in Austria (1), Israel (1), Portugal (1)). By phase: Phase 3 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 6Clinical trials
- 6Countries
Newest Cardiogenic Shock Post Myocardial Infarction clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Ivabradine for cardiogenic shock after a heart attack | Phase 3 | Karachi | Recruiting | Jul 20, 2026 |
| Rapid escalation from Impella CP to Impella 5.5 in cardiogenic shock after myocardial infarction | — | Düsseldorf, North Rhine-Westphalia and 2 other locations | Recruiting | Jun 17, 2026 |
| Optimizing Impella 5.5 Outcomes With Advanced Data Science | — | Vienna | Recruiting | Jun 1, 2026 |
| Cardiogenic Shock Outcomes Registry (COR-SHOCK): how patients fare over time | — | Carnaxide, Lisbon District | Recruiting | May 19, 2026 |
| Outcomes in patients with mixed cardiogenic and vasoplegic shock | — | Amiens, Somme | Recruiting | Jan 21, 2026 |
| Using beta-blockers for heart attack patients in intensive care | — | Tel Aviv | Recruiting | May 13, 2025 |
All recruiting trials (6)
-
Ivabradine for cardiogenic shock after a heart attack
A study tests whether taking ivabradine can help people with cardiogenic shock after a heart attack move down at least one class on the SCAI scale and need less time on blood pressure or heart-support medicines.
-
Rapid escalation from Impella CP to Impella 5.5 in cardiogenic shock after myocardial infarction
This observational study tests whether quickly upgrading from an Impella CP to an Impella 5.5 in patients with heart failure after a heart attack improves outcomes.
-
Optimizing Impella 5.5 Outcomes With Advanced Data Science
This study tests whether real-world data from Impella 5.5 patients with cardiogenic shock can help predict heart recovery and prevent complications, using advanced data science.
-
Cardiogenic Shock Outcomes Registry (COR-SHOCK): how patients fare over time
This observational registry tests how outcomes and management of cardiogenic shock have changed over the years in adults receiving routine care.
-
Outcomes in patients with mixed cardiogenic and vasoplegic shock
This registry will try to describe outcomes and risk factors in adults admitted with cardiogenic shock who also have inappropriate vasodilation (mixed cardiogenic‑vasoplegic shock).
-
Using beta-blockers for heart attack patients in intensive care
This study is testing if the heart medication metoprolol can help heart attack patients in intensive care feel better and avoid worsening their condition.
Related topics
Quick answers
How many Cardiogenic Shock Post Myocardial Infarction clinical trials are recruiting right now?
6, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 6 countries. The most sites are in Austria (1 trial), Israel (1 trial), Portugal (1 trial), France (1 trial), Pakistan (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.